<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    12220783
   </pmid>
   <datecreated>
    <year>
     2002
    </year>
    <month>
     09
    </month>
    <day>
     10
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2002
    </year>
    <month>
     09
    </month>
    <day>
     25
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     10
    </month>
    <day>
     26
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0029-7844
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       100
      </volume>
      <issue>
       3
      </issue>
      <pubdate>
       <year>
        2002
       </year>
       <month>
        Sep
       </month>
      </pubdate>
     </journalissue>
     <title>
      Obstetrics and gynecology
     </title>
     <isoabbreviation>
      Obstet Gynecol
     </isoabbreviation>
    </journal>
    <articletitle>
     Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring.
    </articletitle>
    <pagination>
     <medlinepgn>
      585-93
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To assess the contraceptive efficacy, cycle control, tolerability, and user acceptability of a novel combined contraceptive vaginal ring for up to 13 cycles.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      Healthy women requesting contraception were enrolled in this 1-year multicenter study. Each ring released 120 microg of etonogestrel and 15 microg of ethinylestradiol daily, and was used for 3 weeks followed by a 1-week ring-free period.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      A total of 2322 women started treatment and so formed the intent-to-treat population. Subjects were followed for 23,298 cycles, equivalent to 1786 woman-years. Compliance was good with 85.6% of cycles in full compliance with specified criteria. In the intent-to-treat population, 21 pregnancies occurred, giving a Pearl Index of 1.18 (95% confidence interval 0.73, 1.80). Eleven of the pregnancies were attributable to noncompliance; the Pearl Index for the per-protocol population was 0.77 (95% confidence interval 0.37, 1.40). The mean incidence of withdrawal bleeding was 98.5% in all cycles. Irregular bleeding occurred in 5.5% of all cycles, and in most women, early or late withdrawal bleeding was restricted to spotting. The ring was well tolerated with a low incidence of adverse events; only 2.5% of all discontinuations were device related. The ring was easy to insert and remove and did not interfere with intercourse. Eighty-five percent of women were satisfied with the ring, and 90% would recommend its use to others.
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      The ring is an effective contraceptive with excellent cycle control that is convenient, well tolerated, and highly acceptable to users.
     </abstracttext>
    </abstract>
    <affiliation>
     Clinical Development Department, Contraception, NV Organon, Oss, the Netherlands. thom.dieben@organon.com
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Dieben
      </lastname>
      <forename>
       Thom O M
      </forename>
      <initials>
       TO
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Roumen
      </lastname>
      <forename>
       Frans J M E
      </forename>
      <initials>
       FJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Apter
      </lastname>
      <forename>
       Dan
      </forename>
      <initials>
       D
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     Obstet Gynecol
    </medlineta>
    <nlmuniqueid>
     0401101
    </nlmuniqueid>
    <issnlinking>
     0029-7844
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Contraceptive Agents, Female
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Drug Implants
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Vinyl Compounds
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      54024-22-5
     </registrynumber>
     <nameofsubstance>
      Desogestrel
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      54048-10-1
     </registrynumber>
     <nameofsubstance>
      3-keto-desogestrel
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      57-63-6
     </registrynumber>
     <nameofsubstance>
      Ethinyl Estradiol
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Contraceptive Agents, Female
     </descriptorname>
     <qualifiername majortopicyn="N">
      pharmacology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="Y">
      Contraceptive Devices, Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="Y">
      Desogestrel
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Implants
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Ethinyl Estradiol
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Menstrual Cycle
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Patient Compliance
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Patient Satisfaction
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Sensitivity and Specificity
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Vagina
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Vinyl Compounds
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2002
     </year>
     <month>
      9
     </month>
     <day>
      11
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2002
     </year>
     <month>
      9
     </month>
     <day>
      26
     </day>
     <hour>
      6
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2002
     </year>
     <month>
      9
     </month>
     <day>
      11
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     12220783
    </articleid>
    <articleid idtype="pii">
     S0029784402021245
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

